

1 GRADING prognostic factors for severe and recurrent
2 *Clostridioides difficile* infection: expected and unexpected
3 findings. A systematic review.
4

5 Tessel M. van Rossen^{1*#}, Rogier E. Ooijevaar^{2*#}, Christina M.J.E. Vandenbroucke-Grauls^{1,3}, Olaf M.
6 Dekkers⁴, Ed. J. Kuijper⁵, Josbert J. Keller^{6,7}, Joffrey van Prehn⁵

7

8 ¹ Amsterdam UMC, VU University Medical Center, Medical Microbiology & Infection Control,
9 Amsterdam Infection & Immunity, Amsterdam, The Netherlands

10 ² Amsterdam UMC, VU University Medical Center, Gastroenterology & Hepatology, Amsterdam
11 Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands

12 ³ Aarhus University, Clinical Epidemiology, Aarhus, Denmark

13 ⁴ Leiden University Medical Center, Clinical Epidemiology, Leiden, The Netherlands

14 ⁵ Leiden University Medical Center, Center for Infectious Diseases, Medical Microbiology, Leiden, The
15 Netherlands

16 ⁶ Haaglanden Medical Center, Gastroenterology & Hepatology, the Hague, the Netherlands

17 ⁷ Leiden University Medical Center, Gastroenterology & Hepatology, Leiden, the Netherlands

18

19 *Both authors contributed equally and should be considered first author

20 # Address correspondence to Tessel M. van Rossen, Amsterdam UMC locatie VUmc, PK 2X132, De
21 Boelelaan 1117, Amsterdam, the Netherlands, t.vanrossen@amsterdamumc.nl, telephone number:
22 0031-204440799.

23 Or

24 Rogier E. Ooijevaar, Amsterdam UMC locatie VUmc, PK 2X132, De Boelelaan 1117, Amsterdam, the
25 Netherlands, r.ooijevaar@amsterdamumc.nl, telephone number: 0031-204440799.

26

27 Abstract: 300 words

28 Manuscript: 3635 words

29

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

32

33 Background

34 *Clostridioides difficile* infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide
35 a significant burden for both patients and the healthcare system. Treatment consists of oral
36 antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantation (FMT) reduce the number
37 of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with
38 initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective
39 therapeutic choices.

40

41 Objectives

42 In this systematic review we aimed to identify clinical prognostic factors associated with an increased
43 risk of developing sCDI or rCDI.

44

45 Methods

46 PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from
47 database inception through March, 2021. Study selection was performed by two independent
48 reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort
49 and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in
50 patients ≥ 18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in
51 Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations
52 Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview
53 tables of prognostic factors were constructed to assess the number of studies and the respective
54 direction of an association (positive, negative, or no association).

55

56 Results and conclusions

57 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities
58 were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-
59 associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some
60 variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the
61 current review, which can be attributed to differences in methodology. Risk stratification for
62 sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.

63

64

65

66

67

68

69 Background

70 *Clostridioides difficile* infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide
71 a significant burden for both patients and the healthcare system(1). Antibiotic treatment with oral
72 vancomycin and fidaxomicin are the cornerstone of CDI treatment(2-4). Fidaxomicin reduces the
73 number of recurrences compared to vancomycin (5). Bezlotoxumab, a monoclonal anti-Toxin B
74 antibody, can be added to oral anti-CDI antibiotic therapy and reduces the number or recurrences in
75 patients at high risk to develop rCDI (6). Fecal microbiota transplantation (FMT) is a highly efficacious
76 treatment for rCDI, preventing subsequent recurrences, and can lower mortality risk and disease
77 burden of sCDI (7, 8).

78 The costs of fidaxomicin, bezlotoxumab and FMT are higher compared to those of vancomycin.
79 Identifying patients diagnosed with initial CDI who are at an increased risk of developing a severe
80 episode or recurrences could lead to more cost-effective therapeutic choices. Identifying patients at
81 risk, however, is challenging. Several prediction models have been developed (9-30), yet none has
82 been widely adopted in clinical practice.

83 Objectives

84 In this systematic review we aimed to identify clinical prognostic factors associated with an increased
85 risk of developing sCDI or rCDI.

86 Methods

87 Data sources

88 Two searches were performed to identify risk factors for (1) sCDI and (2) rCDI. The search terms and
89 strategy were constructed by a trained librarian, see **Supplementary data**. PubMed, Embase,
90 Emcare, Web of Science and COCHRANE Library databases were searched on October 4th, 2019. An
91 update of the search was performed on March 13th, 2021. The search was restricted to articles
92 published in English. Meeting abstracts were not considered. The search was not limited by year of
93 publication. References of key papers were assessed for relevant papers.

94 Study eligibility criteria

95 Study eligibility was assessed in a two-step selection process. Two independent reviewers screened
96 title and abstract for potentially eligible articles (TvR and RO); discrepancies were resolved by
97 consensus. Full-text articles were retrieved for eligibility; data extraction and risk of bias assessment
98 of included studies was performed by two researchers (TvR and RO).

99 Inclusion criteria: prospective and retrospective cohort and case-control studies including patients
100 ≥18 years, diagnosed with CDI, and providing an analysis of clinical or laboratory data to predict
101 severe/recurrent CDI.

102 Exclusion criteria: study in specific patient populations with a distinct medical condition other than
103 CDI (e.g. study population comprises only hemodialysis patients), and small studies (less than 30
104 patients with severe/recurrent CDI). Laboratory values that were studied as prognostic factors, but
105 which are not part of the regular work-up in CDI (e.g. assays for specific cytokines). Variables that are
106 part of (some of) the definitions of sCDI (such as leukocytosis) were excluded as prognostic factor for
107 sCDI to avoid circularity.

108 Studies on prognostic factors with conflicting results in the uni- and multivariable or with
109 contradicting results when compared to previous meta-analyses, were assessed and graded by a
110 third researcher (CV-G and JK) and scrutinized by weighing the results by the quality of evidence per
111 study.

112 Outcomes of interest were:

113 1. Severe CDI:

114 a. ESCMID 2014/2021 definition: an episode of CDI with (one or more specific signs and
115 symptoms of) severe colitis or a complicated course of disease, with significant systemic
116 toxin effects and shock, resulting in need for ICU admission, colectomy or death (3, 31,
117 32); or:

118 b. IDSA/SHEA definition: an episode of CDI with a white blood cell count of $\geq 15 \times 10^9$
119 cells/mL or a serum creatinine level > 1.5 mg/dL or increase of 50% or greater from
120 baseline(33); or:

121 c. Any other author-constructed definition of severe/complicated/fulminant/fatal CDI.
122

123 2. Recurrent CDI: Recurrence is a new episode of CDI within 2-12 weeks after a previous episode,
124 provided the symptoms of the previous episode resolved after completion of initial treatment
125 (34, 35).

126 Assessment of risk of bias

127 Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool (36), which is
128 recommended by the Cochrane Prognosis Methods Group. The QUIPS tool appraises six domains: (1)
129 study participation, (2) study attrition, (3) prognostic factor measurement, (4) outcome
130 measurement, (5) study confounding and (6) statistical analysis and reporting. The overall risk of bias
131 per study is scored as low, moderate, or high.

132 Quality assessment and data synthesis

133 The quality of evidence per study was assessed by using the Grading of Recommendations
134 Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies (**Figure 1**)
135 (37). This tool is recommended by the Cochrane Prognosis Methods Group and consists of eight
136 domains. The starting point for the quality of evidence is based on the phase of investigation. The
137 quality can be up- or downgraded according to seven other domains. The QUIPS score is included in
138 the second domain ('Study limitations/risk of bias') of the GRADE tool. The outcome of this
139 assessment is the quality of evidence per study, which can be very low (+), low (++), moderate (+++)
140 or high (++++).

141 Overview tables of prognostic factors were constructed to assess the number of studies and the
142 respective direction of an association, i.e. positive, negative, or no association based on effect
143 estimates, 95% CI intervals and p values, stratified by univariate and multivariate analyses. Similar
144 prognostic factors (e.g. coronary artery disease and myocardial infarction) were combined to one
145 factor for a more compact overview. No formal meta-analyses were performed.

8 domains		Score
1. Phase of investigation	1=association / 2=independent association / 3=underlying mechanism Quality of evidence: + very low / ++ low / +++ moderate / ++++ high	1/2/3 + - ++++
2. Study limitations	risk of bias (QUIPS)	✓/✗
3. Inconsistency	heterogeneity in results across studies	✓/✗
4. Indirectness	subset of population of interest/prognostic factor/outcome	✓/✗
5. Imprecision	sample size (calculation), ≥10 patients with outcome per prognostic factor	✓/✗
6. Publication bias	factor is repetitively investigated, ideally by phase 2-3 studies	✓/✗
7. Effect size	moderate/large similar effect is reported by most studies	✓/✗
8. Dose-effect	(continuous/ordinal variables)	✓/✗


Quality of evidence is up- or downgraded depending on domains 2-8

146
147 **Figure 1.** Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for
148 prognostic studies. The final outcome is the overall quality of evidence per study, which can be very low (+), low
149 (++) , moderate (+++) or high (++++).

150

151 Results

152 The search for prognostic factors for sCDI yielded 1242 references; 126 studies were assessed in
153 more detail and 76 were included for analysis (20, 24, 25, 29, 38-109); twelve more studies retrieved
154 from cross-references were also included (110-121) resulting in 88 studies for final analysis (**Figure**
155 **2**). The search for prognostic factors for rCDI yielded 1104 references; 105 studies were assessed in
156 more detail and 36 were included for analysis (9, 10, 12-15, 102, 109, 122-149) as were seven studies
157 from cross-references.) (111, 150-155). This resulted in 43 studies for final analysis (**Figure 2**).
158 Additionally, data of the pivotal RCTs on fidaxomicin and bezlotoxumab were used to support
159 findings (156-160).



160
161 **Figure 2.** Flow diagram of the selection process of studies on prognostic factors for severe/recurrent CDI

162 Prognostic factors for severe CDI

163 The overall quality of evidence ranged from very low to moderate, mainly due to the retrospective
164 nature and small sample size of most studies. The prognostic factors studied in five or more articles
165 are shown in **Table 1**.

166 *Age* was the most studied prognostic factor, and was investigated in 53 of 88 included studies (20,
167 24, 25, 29, 38-42, 44, 46-49, 52, 54, 55, 57, 59, 61-64, 66, 70, 71, 75, 77, 78, 80, 81, 83, 85-88, 91-94,
168 96, 97, 100, 104, 106, 109-111, 113, 114, 116-118). Fifty-one studies performed a univariate analysis
169 and 40 studies (also) a multivariable analysis; 37/51 studies reported *higher age* as risk factor for
170 sCDI in univariate analysis, and 26/40 studies in multivariable analysis (overall moderate quality of
171 evidence).

172 Thirty-two studies assessed the presence of *multiple comorbidities* as risk factor for sCDI (25, 38-42,
173 46-49, 52, 62, 66, 70, 72-74, 80, 81, 85, 87, 88, 91-94, 96, 97, 109, 114, 116, 117); 20/30 studies
174 found an association between the presence of *multiple comorbidities* and sCDI in univariate analysis
175 and 11/23 studies in multivariable analysis (moderate quality of evidence).

176 For both higher age and the presence of multiple comorbidities a dose effect was observed: the
177 higher the age or the more concurrent disorders, the higher the risk of severe disease. No specific
178 medical condition was associated with sCDI.

179 For clinical decision making, a specific cut-off value for age and number of comorbidities would be
180 convenient. However, in many studies age was used as a continuous variable (31/53 studies) or
181 varying cut-off values are used. The majority of studies found a higher risk for sCDI in patients older
182 than 65-70 years. For comorbidity, different established or self-constructed comorbidity scores were
183 reported, the Charlson Comorbidity Index (CCI) most frequently (161). Again, most studies used CCI
184 as continuous variable. Of the studies that identified more comorbidities as risk factor for sCDI, only
185 three used a cut-off value: one study reported a higher risk in patients with a CCI of ≥ 3 , and two
186 found a higher risk in patients with ≥ 2 comorbidities (88, 93, 96). Thus, no statement can be made on
187 the association between exact numbers of comorbidities and severe CDI.

188 Twenty articles studied the association between the presence of NAP1/RT027 strain and sCDI (44-46,
189 56, 60, 61, 73, 74, 81, 84, 85, 88, 89, 91, 94, 96, 100, 101, 108, 111); 8/19 studies reported a higher
190 risk of sCDI in patients with NAP1/027 strain in univariate analysis, and 5/10 in multivariate analysis.
191 One study found that NAP1/027 was more prevalent in patients with mild disease compared to
192 patients with sCDI (44).

193 Furthermore, seven studies assessed *C. difficile* binary toxin as risk factor for sCDI (45, 82, 91, 94,
194 117, 119, 121). Of these, three identified *C. difficile* binary toxin as a risk factor for sCDI in univariate
195 analysis, and only 1/1 study in multivariate analysis. The overall quality of evidence of these studies
196 was low. We scrutinized the separate studies on the presence of NAP1/RT027 strain and/or binary
197 toxin by weighing the results by the quality of evidence per study, but this did not alter the
198 conclusion.

199 Another interesting finding was that the majority of studies did not find an association between the
200 use of *PPIs*, *H2 receptor antagonists* or *antibiotics* and the occurrence of sCDI in uni- and multivariate
201 analyses. However, the quality of evidence was low.

202 In conclusion, only the factors *higher age (>65-70 years old)* and the presence of *multiple*
203 *comorbidities* were consistently associated with sCDI (**Table 3**).

Potential prognostic factor	Number of participants	Number of studies	Univariate			Multivariate			GRADE factors								
			+	0	-	+	0	-	Phase	Study limitations	Inconsistency	Indirectness	Imprecision	Publication bias	Moderate/large effect size	Dose effect	Quality of evidence
Demographics																	
Higher age	4,240,336	53	37	14	0	26	14	0	1	×	✓	✓	✓	✓	✓	✓	+++
Gender*	4,224,842	40	6M	31	2F	2M	12	2F	1	×	✓	✓	✓	✓	×	×	++
Caucasian ethnicity	1,266,818	9	2	7	0	1	3	0	1	×	✓	✓	✓	✓	×	×	++
Comorbidities																	
More comorbidities	4,213,584	32	20	10	0	11	12	0	1	×	✓	✓	✓	✓	✓	✓	+++
Cardiovascular	1,287,293	19	8	10	0	5	7	0	1	×	×	✓	✓	✓	×	×	++
Pulmonary	1,345,420	16	6	9	0	3	6	0	1	×	×	✓	✓	✓	×	×	++
Neurological	88,881	11	1	8	1	1	4	0	1	×	✓	✓	✓	✓	×	×	++
ADL dependency	4,261	6	4	1	0	2	3	0	1	×	×	✓	✓	✓	×	×	+
Infection	4,900	7	3	3	0	1	3	0	1	×	×	✓	✓	✓	×	×	++
Malignancy	1,346,642	21	7	13	0	4	5	0	1	×	✓	✓	✓	✓	×	×	++
Chronic renal disease	2,875,427	24	7	16	0	6	2	0	1	×	✓	✓	✓	✓	×	×	++
Liver disease	1,343,798	11	2	8	0	2	3	0	1	×	✓	✓	✓	✓	×	×	++
Inflammatory bowel disease	79,856	6	1	4	1	1	1	1	1	×	✓	✓	✓	✓	×	×	++
Diabetes mellitus	1,357,184	24	4	16	3	2	8	2	1	×	✓	✓	✓	✓	×	×	++
Immunocompromised	95,665	26	9	17	0	6	6	0	1	×	✓	✓	✓	✓	×	×	++
Under- or overweight~	1,263,658	6	1	6	0	1	2	0	1	×	✓	✓	✓	✓	×	×	++
Medication																	
Acid suppression/peptic ulcer disease	83,876	11	4	7	0	3	3	0	1	×	×	✓	✓	✓	×	×	++
PPIs	8,521	17	3	14	0	0	4	0	1	×	✓	✓	✓	✓	×	×	++
H2 receptor antagonists	4,564	9	2	7	0	1	1	0	1	×	✓	✓	✓	✓	×	×	++
Antibiotic use¶	11,985	24	4	19	0	3	5	0	1	×	✓	✓	✓	✓	×	×	++
Fluoroquinolones	4,053	9	1	8	0	0	2	0	1	×	✓	✓	✓	✓	×	×	++
Antiperistaltics	2,559	5	0	5	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Recent medical history																	
Previous surgery	10,433	8	2	6	0	1	1	0	1	×	✓	✓	✓	✓	×	×	++
Malnutrition/(par)enteral feeding	4,190	8	2	6	0	1	3	0	1	×	✓	✓	✓	✓	×	×	++
CDI factors																	

Healthcare facility associated	13,677	30	10	20	0	2	10	0	1	×	✓	✓	✓	×	×	×	+
Community associated	3,093	6	1	5	0	0	1	0	1	×	✓	✓	✓	✓	×	×	++
NAP1/027 strain	10,141	20	8	10	1	5	4	1	2	×	×	✓	✓	✓	×	×	++
Binary toxin	3,836	7	3	5	0	1	0	0	2	✓	×	✓	✓	✓	×	×	++
Positive toxin EIA	9,642	9	6	3	0	3	2	0	1	×	×	✓	✓	✓	×	×	++
Prior CDI (>3 months)	2,341	5	0	5	0	0	2	0	1	×	✓	✓	✓	✓	×	×	++
Recurrent CDI (<3 months)	12,842	5	3	2	0	1	1	0	1	×	×	✓	✓	✓	×	×	+
Laboratory values																	
Anemia	6,121	9	4	5	0	2	3	0	1	×	×	✓	✓	✓	×	×	+
Thrombocytopenia	5,125	6	4	2	0	2	2	0	1	×	×	✓	×	✓	×	×	+
Electrolyte imbalance	1,263,366	3	3	0	0	1	2	0	1	×	×	✓	✓	✓	×	×	+

Table 1. Potential prognostic factors for severe CDI. Phase, phase of investigation. For uni- and multivariate analyses: +, number of significant effects with a positive value; 0, number of non-significant effects; -, number of significant effects with a negative value. For GRADE factors: ✓, no serious limitations; ×, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high.

* M = male; F = female. In 4 studies male gender and in 2 studies female gender was identified as prognostic factor for severe CDI in univariate analysis. In multivariate analysis, 2 studies reported male gender and 2 studies reported female gender as risk factor of sCDI.

~ One study analyzed both under- and overweight as prognostic factors for sCDI; this study identified underweight but not overweight as risk factor for sCDI in uni- and multivariate analyses.

¶ Besides from antibiotic use (yes/no) prior to CDI diagnosis, none of the following separate antibiotic class was found to be predictive of sCDI: cephalosporins (n=7 studies), penicillins (n=4), macrolides (n=4), glycopeptides (n=3). Results for carbapenems were inconsistent with a tendency towards 'no effect' (n=8).

^ Publication bias is probable since most prognostic studies for sCDI are performed in hospitalized patients

Seven studies assessed the presence of *C. difficile* binary toxin as prognostic factor for sCDI. Of these, one study contained two cohorts: in univariate analysis, binary toxin was associated with sCDI in one cohort, but not in the other cohort (121). Both results are reported in the results columns of the univariate analyses. Therefore, in this table the number of studies on binary toxin is 7, but the total number of univariate analyses is 8.

§ One large prospective study (Berry et al) and one small prospective study (López-Cárdenas) found binary toxin as risk factor for severe CDI and/or mortality; one large retrospective study (Carlson et al) found that the combination of binary toxin and eosinopenia was associated with mortality; two smaller prospective studies and two retrospective studies did not identify binary toxin as risk factor for sCDI.

204 Prognostic factors for recurrent CDI

205 The overall quality of evidence for the prognosis of recurrent CDI (rCDI) was low to moderate (**Table**
206 **2**). The majority of studies was retrospective, with a high to moderate risk of bias.

207 *Higher age (≥65 years old)* is the most studied factor and was investigated in 35/43 included studies
208 (9, 10, 12-15, 109, 111, 122, 123, 125, 126, 128, 130-134, 136-141, 143-153), 15/30 studies identified
209 higher age as risk factor for rCDI in univariate analysis, and 16/31 studies in multivariable analysis.
210 Moreover, higher age was the only factor for which we found a moderate to large effect size and a
211 dose-dependent effect.

212 Eight studies assessed whether a *previous CDI recurrence in the preceding 3 months* was a risk factor
213 for a subsequent rCDI, and showed inconsistent results (9, 10, 15, 111, 125, 133, 140, 145). Two
214 prospective studies of higher quality found a clear association of previous recurrence with the risk of
215 a subsequent rCDI (111, 140). Also, data of the pivotal trials on fidaxomicin and bezlotoxumab
216 indicate that recurrence rates are higher in patients with any previous CDI episode or patients that
217 fulfill criteria for rCDI (156-160). Since these trials are considered high quality studies, we have
218 upgraded the level of evidence from low to moderate (Table 3). Finally, we consider two or more
219 episodes of CDI as risk factor for a subsequent rCDI.

220 *Healthcare-acquired CDI* was associated with rCDI in univariate analyses of 5/10 studies, and in
221 multivariable analyses of 2/4 studies (9, 14, 111, 125, 128, 141, 144, 145, 149, 150). This is also
222 reflected by the correlation of *prior hospitalization (<3 months)* with a recurrent episode of CDI (13,
223 15, 125, 128, 133, 138, 143, 149). The two largest cohort studies showed a significant association
224 between prior hospitalization and rCDI in uni- and multivariable analysis (128, 149). Of note, one
225 large cohort study reported a protective effect of community-acquired CDI for the development of
226 rCDI (128).

227 *Proton pump inhibitor use* was studied in 23 included studies (9, 13, 14, 109, 122, 123, 130-135, 137,
228 139, 141, 145, 147-151, 153, 155). The results show no clear association between PPIs and rCDI in
229 univariate analyses, while in multivariable analyses there appears to be an association. Of note, some
230 studies made a distinction between the moment PPI was started, i.e. prior to initial CDI episode or
231 during/shortly after the initial episode (12, 13, 15, 123, 125, 146, 149, 155); PPI prescribed during or
232 shortly after initial CDI appears to be associated with an increased risk of rCDI (effect found in 6/7
233 studies in univariate analysis, and in 2/4 studies in multivariable analysis; low quality of evidence).

234 Eight studies reported on *non-CDI antibiotic use* after initial CDI diagnosis as a risk factor, but results
235 were inconsistent (12, 123, 129, 136, 141, 145, 146, 148); 4/6 studies found an association between
236 non-CDI antibiotic use and rCDI in univariate analysis, and 2/5 studies in multivariable analysis. A
237 high-quality prospective study showed no significant association between antibiotic use and rCDI in
238 both uni- and multivariate analysis (136). Several other studies investigated whether specific
239 antibiotics that incited the primary CDI episode, were associated with recurrence; none of these
240 antibiotic drugs was associated with rCDI. In conclusion, nor non-CDI antibiotic use prior to the
241 primary CDI, nor concomitant non-CDI antibiotics used during the primary CDI episode, appeared to
242 be convincing predictors for rCDI.

243 Although various definitions of sCDI are used in prognostic studies, most studies did not find severity
244 of CDI to be a prognostic factor for rCDI (9, 123, 126, 131, 134, 140-142, 147, 150); 2/7 studies

245 identified sCDI as risk factor for rCDI in univariate analysis, and 2/4 in multivariable analysis. In the
246 MODIFY trials, sCDI was a prespecified risk factor for recurrence, but in the placebo arm the
247 recurrence rate was lower in the sCDI subgroup (22.4%) than in the non-CDI subgroup (27.5%) (158).
248 Since we expected sCDI to be a risk factor for rCDI, re-assessment of included studies was performed
249 by a third researcher (CV-G); this did not alter our results. In conclusion, we found insufficient
250 evidence to consider sCDI a risk factor for rCDI.

251 Several studies investigated specific comorbidities, including chronic renal failure, diabetes mellitus,
252 and cardiovascular disease as risk factors for rCDI (9, 12-15, 111, 122, 123, 125, 126, 128, 130-134,
253 136, 138-154). Our review does not show any of these comorbidities to be clearly associated with an
254 increased risk for rCDI. Even when combined into a robust score such as the Charlson Comorbidity
255 Index, we did not identify a clear association (13, 65, 122, 130, 132-134, 140, 145, 146, 148, 150,
256 152). Since results of the uni- and multivariable analyses of studies reporting in renal failure were
257 conflicting, these studies were re-assessed by a third researcher. This led to identical findings.
258 Immunocompromised status was a prespecified risk factor in the MODIFY trials; though in the
259 placebo arm the recurrence rate in immunocompromised patients did not differ from that in
260 immunocompetent patients (27.5% vs 26.6%) (158). A post-hoc analysis of the pivotal fidaxomicin
261 trials investigated fever, leukocytosis and renal failure as prognostic markers, and identified renal
262 failure as the only significant predictor for recurrence (RR, 1.45; 95% CI, 1.05–2.02). Overall, we
263 found insufficient evidence to consider other comorbidities a risk factor for rCDI.

264 The ribotype 027 strain was not clearly associated with recurrence. However, only five studies
265 reported on this ribotype as a possible risk factor (111, 123, 129, 145, 148); 2/5 studies found that
266 the presence of a RT027 strain was associated with sCDI in univariate analysis, and only 1/3 studies in
267 multivariable analysis. Since these results were inconsistent when compared to a previous systematic
268 review, results were re-assessed by a third researcher (162). This reassessment did not result in
269 different conclusions.

270 Laboratory parameters studied include white blood cell counts, and levels albumin, creatinine and C-
271 reactive protein. None of these parameters was clearly associated with rCDI (10, 12-15, 111, 134,
272 141, 144-147, 149).

273 Our findings show the use of probiotics as prophylaxis for CDI seemed to be associated with rCDI (13,
274 14, 123, 133). However, this association is based on a small number of studies (n=4) and might be
275 confounded by the fact that probiotics are started in patients with a high risk of rCDI and/or
276 concomitant antibiotic use.

Potential prognostic factor identified	Number of participants	Number of studies	Univariate			Multivariable			GRADE factors								
			+	0	-	+	0	-	Phase	Study limitations	Inconsistency	Indirectness	Imprecision	Publication bias	Moderate/large effect size	Dose effect	Quality of evidence
Demographics																	
Higher age	52,312	35	15	15	0	16	5	0	1	×	×	✓	✓	✓	✓	✓	+++
Gender	7,074	8	0	7	0	0	1	0	1	×	✓	✓	✓	✓	×	×	++
<i>Male</i>	15,769	10	2	7	0	1	1	0	1	×	✓	✓	✓	✓	×	×	++
<i>Female</i>	5,833	12	2	9	0	1	2	0	1	×	✓	✓	✓	✓	×	×	++
Community-acquired CDI	13,837	7	1	5	1	1	1	0	1	×	✓	✓	✓	✓	×	×	++
Hospital-acquired CDI	10,468	10	5	5	0	2	2	0	1	×	×	✓	✓	✓	×	×	++
Caucasian race	13,335	3	2	1	0	1	0	0	1	×	×	✓	✓	✓	×	×	+
CDI factors																	
Severe CDI	8,796	10	2	7	0	2	2	0	1	×	✓	✓	×	✓	×	×	+
Ribotype 027 strain	6,921	5	2	3	0	1	2	0	1	×	×	✓	✓	✓	×	×	++
Recurrent CDI episode (<3 months)	20,868	8	2	3	0	3	1	0	1	×	×	✓	✓	✓	×	×	++
Comorbidities																	
Charlson comorbidity index	30,045	13	2	7	0	2	4	0	1	×	✓	✓	✓	✓	×	×	++
Cardiovascular (CHF/MI)	20,160	11	4	7	0	0	1	0	1	×	✓	✓	×	✓	×	×	++
Peripheral vascular disease	18,318	6	2	4	0	0	0	0	1	×	×	✓	×	✓	×	×	+
Cerebrovascular (stroke)	17,785	6	2	4	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
(Chronic obstructive) Pulmonary disease	19,908	11	1	10	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
(Chronic) Renal disease/failure	26,440	19	3	15	0	2	1	0	1	×	✓	✓	✓	✓	×	×	+++
Diabetes mellitus	20,745	14	2	12	0	1	0	0	1	×	✓	✓	✓	✓	×	×	+++
Liver disease	14,378	8	0	8	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Inflammatory bowel disease	13,977	6	3	3	0	1	2	0	1	×	×	✓	✓	✓	×	×	++
Dementia	12,458	5	1	4	0	0	0	0	1	×	×	✓	✓	✓	×	×	++
Malignancy	13,685	10	0	10	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
<i>Solid malignancy</i>	10,078	4	1	3	0	0	0	0	1	×	✓	✓	✓	✓	×	×	+
Hospital admission factors																	
Prior hospitalization (<3 months)	31,952	8	5	2	0	2	2	0	1	×	×	✓	✓	✓	×	×	++
Requirement of ICU admission	28,356	8	2	4	0	0	3	0	1	×	✓	✓	✓	✓	×	×	++
Increased length of stay (>10 days)	2,464	5	3	2	0	1	2	0	1	×	×	✓	✓	✓	×	×	+
Medication																	
Concomitant non-CDI AB	7,980	8	2	4	0	2	3	0	1	×	×	✓	✓	✓	×	×	+
Proton pump inhibitor	43,653	23	6	14	1	8	3	1	1	×	×	✓	✓	✓	×	×	++
<i>PPI prior to CDI</i>	14,308	5	2	3	0	0	0	0	1	×	×	✓	✓	✓	×	×	+
<i>PPI during/after CDI</i>	11,785	7	6	1	0	2	2	0	1	×	✓	✓	✓	✓	×	×	++
H2 receptor antagonist	29,998	5	2	2	0	2	1	0	1	×	✓	✓	✓	✓	×	×	++
Steroids / immunosuppression	11,429	10	3	6	0	2	3	0	1	×	✓	✓	✓	✓	×	×	++

Probiotics	29,847	4	3	0	0	2	1	0	1	×	✓	✓	✓	✓	×	×	++
Chemotherapy	20,494	8	0	7	0	1	1	0	1	×	✓	✓	✓	✓	×	×	++
Parenteral feeding	2,988	7	1	6	0	0	0	0	1	×	✓	✓	✓	×	×	×	+
Inciting AB																	
Aminopenicilin	10,435	5	1	4	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Cephalosporin	4,086	4	0	4	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Fluorquinolones	15,657	12	3	9	0	2	0	0	1	×	✓	✓	✓	✓	×	×	++
Aminoglycoside	10,271	4	1	3	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Clindamycin	10,679	5	2	3	0	1	0	0	1	×	×	✓	✓	✓	×	×	+
Macrolide	10,435	5	1	4	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Carbapenem/meropenem	9,938	7	0	7	0	0	0	0	1	×	✓	✓	✓	✓	×	×	++
Laboratory values																	
Leukocytes (mean/peak)	22,954	17	6	10	0	1	3	0	1	×	✓	✓	✓	✓	×	×	++
Albumin (mean/low)	18,737	12	4	8	0	1	2	0	1	×	✓	✓	✓	✓	×	×	++
Creatinine (mean/peak)	19,651	14	1	12	0	1	2	0	1	×	✓	✓	✓	✓	×	×	+++
C-reactive protein	9,805	5	2	2	0	0	0	0	1	×	×	✓	✓	✓	×	×	+
Symptoms																	
Fever	3,740	9	3	6	0	2	0	0	1	×	✓	✓	✓	✓	×	×	++
Abdominal pain	5,756	5	2	3	0	0	0	0	1	×	×	✓	✓	✓	×	×	+

Table 2. Potential prognostic factors for recurrent CDI. Phase, phase of investigation. For uni- and multivariate analyses: +, number of significant effects with a positive value; 0, number of non-significant effects; -, number of significant effects with a negative value. For GRADE factors: ✓, no serious limitations; ✗, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

Prognostic factor	Quality of evidence
<i>Severe CDI</i>	
Higher age (>65-70 years old)	moderate
Presence of multiple comorbidities	moderate
<i>Recurrent CDI</i>	
Higher age (>65-70 years old)	moderate
Previous recurrence of CDI (<3 months)	moderate
Healthcare-associated CDI	low
Prior hospitalization (<3 months)	low
Proton pump inhibitors started during/after CDI diagnosis	low

277 **Table 3.** Summary of findings

278 Conclusions

279 In this systematic review, we applied the GRADE methodology to weigh the evidence on prognostic
 280 factors for sCDI and rCDI (37). We found that the most important risk factors for sCDI were higher
 281 age (≥ 65 -70 years old) and presence of multiple comorbidities. Higher age was also a prognostic
 282 factor for rCDI. Other factors associated with an increased risk of rCDI were the acquisition of CDI as
 283 a healthcare-associated infection and prior hospitalization and the start of PPIs during/after CDI
 284 diagnosis. The evidence for having a previous recurrence of CDI as risk factor for rCDI was less strong.

285 Our systematic review on prognostic factors resulted in several expected and unexpected findings
 286 when compared with previous reviews rCDI (162-164). Our findings are in line with two recently
 287 published systematic reviews on predictors of sCDI that reported age and presence of comorbidities
 288 as the two most important severity predictors for CDI (162, 165). Similarly, previous reviews on
 289 prognostic factors for rCDI found that older age, prior CDI and PPI therapy were risk factors for rCDI
 290 (162-165). However, PPI therapy in general did not show a clear association in our study.

291 In contrast, we could not clearly identify several previously reported risk factors for sCDI or rCDI, such
 292 as infection caused by a ribotype 027/NAP1 strain, antibiotic use, PPI use prior to CDI diagnosis, and
 293 the presence of chronic or end-stage renal disease (162, 163). One possible explanation might be
 294 that many reviews excluded studies reporting solely univariate analyses. This might lead to an
 295 overestimation of the effect of certain prognostic factors, since many studies only include variables
 296 with a significant association in univariate analysis in their multivariable analysis. Another
 297 explanation for our findings might be index event bias: this bias arises in studies that select patients
 298 based on the occurrence of an index event, and can lead to 'negative' or even paradoxical findings in
 299 recurrence risk research (166). Here, we found that chronic renal failure did not appear to be
 300 associated with rCDI. Previous research shows that patients with kidney failure are prone to
 301 developing a primary CDI, but the direct association between kidney disease and rCDI is less clear
 302 (163, 167). Since reviews on rCDI select studies based on the occurrence of a primary CDI, this might
 303 explain why renal disease is not a strong predictor of rCDI in previous reviews, and not a significant
 304 risk factor in the current review.

305 Finally, when studying IBD as prognostic factor for sCDI/rCDI, another difficulty in interpretation
306 arises, since symptoms of IBD are similar to those of CDI. Furthermore, patients with IBD are at
307 higher risk of CDI and infection and colonization with *C. difficile* can induce an exacerbation of IBD
308 (168). Also, diagnostic tests do not always allow to differentiate between *C. difficile* infection or
309 colonization. Many clinicians pragmatically start antibiotic treatment in IBD patients without
310 endoscopy. Subsequent false-positive CDI diagnoses may contribute to an overestimation of CDI
311 (recurrence) risk. Aforementioned factors may have contributed to differences between the results
312 of our current review and previous publications.

313 Our review has several strengths. First, we used a broad search strategy and included a large number
314 of studies, minimizing the risk of missing data. Second, articles were selected based on strict
315 predefined criteria by two independent researchers (TvR and RO). Third, the quality of the studies
316 was judged by the structured prognostic GRADE approach. To our knowledge this approach has not
317 been previously used for prognostic factors for sCDI and rCDI. Also, we reported results of both uni-
318 and multivariable analyses. When results of the uni- and multivariable analyses of different studies
319 were conflicting, we acknowledged this disparity and results were re-assessed by a third researcher.
320 Reassessment was performed on the studies reporting the presence of RT027 strain, sCDI and renal
321 disease as possible risk factors for rCDI, but this did not result in different conclusions. Finally, some
322 disparity can be explained by the large number of studies where non-significant univariate prognostic
323 factors were not included in the multivariate models.

324 A limitation is the generally low quality of available studies. Most studies have not performed a
325 sample size calculation, allowing for possible type I and type II statistical errors. As many studies
326 were retrospective, it was not always clear whether certain factors were already present before the
327 occurrence of sCDI/rCDI (i.e. truly prognostic factors) or whether they co-existed. A second important
328 limitation is the subjectivity how to weight different quality studies, which also resulted in
329 stimulating discussions in our working group.

330 Identifying prognostic factors for sCDI and rCDI could aid clinicians to make an optimal treatment
331 decision to reduce the risk of recurrent disease and decrease CDI complications. The findings of this
332 review are especially relevant for rCDI: a risk stratification strategy may allow for selective use of
333 more expensive novel treatments with less risk of recurrence. To implement risk stratification of in
334 clinical practice, simple risk tools are needed. Currently, several prediction models or risk scores for
335 sCDI and rCDI have been developed (9-30). However, none has gained widespread clinical
336 implementation. Based on the low quality of the studies and small effects of identified prognostic
337 factors, it is not surprising that validation of prediction tools in external cohorts show disappointing
338 results (169-171). Additional explanations are the heterogeneity and multimorbidity of the CDI
339 population and variation in study setting, diagnostic criteria and CDI treatment regimens. The
340 current review may be used as starting point for the development of a risk tool with a better
341 performance in the overall CDI population. We suggest that future clinical trials on CDI treatment use
342 standardized definitions for recurrence and severity and systematically collect and report the risk
343 factors that we have discussed in this review, to allow for meaningful meta-analysis on risk factors
344 using data of high-quality trials.

345 In conclusion, our approach identified higher age and the presence of multiple comorbidities as
346 prognostic factors for sCDI. The only identified risk factors for rCDI were higher age, healthcare-
347 associated CDI, prior hospitalization (<3 months), PPIs started during/after CDI diagnosis and rCDI.

348 Some variables that were found as risk factors for sCDI/rCDI in previous reviews, were not confirmed
349 in the current review, which can be attributed to differences in methodology. Risk stratification for
350 sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.

351 Transparency declaration

352 Conflict of interest disclosures, funding

353 TvR was supported by Netherlands Organization for Health Research and Development (ZonMw)
354 grant *Goed Gebruik Geneesmiddelen*, project number 848016009. JK and EK received a research
355 grant from Vedanta Biosciences (Boston, USA). The funders had no role in study design, data
356 collection and interpretation, or the decision to submit the work for publication. All other authors: no
357 conflicts of interest to disclose.

358 Contribution

359 JP and EK conceived the study on behalf of the *ESCMID Study Group for Clostridioides difficile*
360 (ESGCD). JP designed the search strategy. TvR and RO selected the studies and acquired the data.
361 TvR, RO, CV-G and JK graded selected studies. TvR, RO and OD analyzed the data. TvR and RO drafted
362 the manuscript. All authors critically revised the manuscript and approved the final version.

363 References

- 364 1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of *Clostridium*
365 *difficile* infection in the United States. *N Engl J Med*. 2015;372(9):825-34.
- 366 2. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice
367 Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious
368 Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin*
369 *Infect Dis*. 2018;66(7):987-94.
- 370 3. Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical M, Infectious D. European
371 Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document
372 for *Clostridium difficile* infection. *Clin Microbiol Infect*. 2014;20 Suppl 2:1-26.
- 373 4. Ooijsaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, et al. Update of
374 treatment algorithms for *Clostridium difficile* infection. *Clinical microbiology and infection : the*
375 *official publication of the European Society of Clinical Microbiology and Infectious Diseases*.
376 2018;24(5):452-62.
- 377 5. Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for
378 *Clostridium difficile* infection: a systematic review and network meta-analysis. *Lancet Infect Dis*.
379 2018;18(9):1035-44.
- 380 6. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for
381 Prevention of Recurrent *Clostridium difficile* Infection. *N Engl J Med*. 2017;376(4):305-17.
- 382 7. Ianiro G, Masucci L, Quaranta G, Simonelli C, Rizzatti G, Lopetuso L, et al. Randomized Clinical
383 Trial: Single-Infusion Fmt Versus Multiple-Infusion Fmt for the Treatment of Severe *C. Difficile*
384 Infection. *Digest Liver Dis*. 2018;50(2):E66-E7.
- 385 8. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal
386 infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013;368(5):407-15.
- 387 9. Cobo J, Merino E, Martinez C, Cozar-Lliso A, Shaw E, Marrodan T, et al. Prediction of
388 recurrent *clostridium difficile* infection at the bedside: the GEIH-CDI score. *Int J Antimicrob Agents*.
389 2018;51(3):393-8.
- 390 10. D'Agostino RB, Sr., Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent
391 *Clostridium difficile* infection based on clinical factors. *Clin Infect Dis*. 2014;58(10):1386-93.

- 392 11. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a
393 recurrent *Clostridium difficile* risk-prediction model. *J Hosp Med*. 2014;9(7):418-23.
- 394 12. Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, Rodriguez V, Ferrer C, Bartolome R,
395 et al. First recurrence of *Clostridium difficile* infection: clinical relevance, risk factors, and prognosis.
396 *European journal of clinical microbiology & infectious diseases* : official publication of the European
397 Society of Clinical Microbiology. 2016;35(3):371-8.
- 398 13. Reveles KR, Mortensen EM, Koeller JM, Lawson KA, Pugh MJV, Rumbellow SA, et al.
399 Derivation and Validation of a *Clostridium difficile* Infection Recurrence Prediction Rule in a National
400 Cohort of Veterans. *Pharmacotherapy*. 2018;38(3):349-56.
- 401 14. Viswesh V, Hincapie AL, Yu M, Khatchatourian L, Nowak MA. Development of a bedside
402 scoring system for predicting a first recurrence of *Clostridium difficile*-associated diarrhea. *Am J*
403 *Health Syst Pharm*. 2017;74(7):474-82.
- 404 15. Hebert C, Du H, Peterson LR, Robicsek A. Electronic health record-based detection of risk
405 factors for *Clostridium difficile* infection relapse. *Infect Control Hosp Epidemiol*. 2013;34(4):407-14.
- 406 16. LaBarbera FD, Nikiforov I, Parvathenani A, Pramil V, Gorrepati S. A prediction model for
407 *Clostridium difficile* recurrence. *J Community Hosp Intern Med Perspect*. 2015;5(1):26033.
- 408 17. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and
409 validation of a clinical prediction rule for recurrent *Clostridium difficile* infection. *Gastroenterology*.
410 2009;136(4):1206-14.
- 411 18. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in
412 *Clostridium difficile* infection: a systematic review. *PloS one*. 2012;7(1):e30258.
- 413 19. Arora V, Kachroo S, Ghantaji SS, Dupont HL, Garey KW. High Horn's index score predicts poor
414 outcomes in patients with *Clostridium difficile* infection. *The Journal of hospital infection*.
415 2011;79(1):23-6.
- 416 20. Bhangu S, Bhangu A, Nightingale P, Michael A. Mortality and risk stratification in patients
417 with *Clostridium difficile*-associated diarrhoea. *Colorectal disease : the official journal of the*
418 *Association of Coloproctology of Great Britain and Ireland*. 2010;12(3):241-6.
- 419 21. Butt E, Foster JA, Keedwell E, Bell JE, Titball RW, Bhangu A, et al. Derivation and validation of
420 a simple, accurate and robust prediction rule for risk of mortality in patients with *Clostridium difficile*
421 infection. *BMC Infect Dis*. 2013;13:316.
- 422 22. Drew RJ, Boyle B. RUWA scoring system: a novel predictive tool for the identification of
423 patients at high risk for complications from *Clostridium difficile* infection. *The Journal of hospital*
424 *infection*. 2009;71(1):93-4; author reply 4-5.
- 425 23. Hensgens MP, Dekkers OM, Goorhuis A, LeCessie S, Kuijper EJ. Predicting a complicated
426 course of *Clostridium difficile* infection at the bedside. *Clin Microbiol Infect*. 2014;20(5):O301-8.
- 427 24. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for
428 *Clostridium difficile* infection at the time of admission. *The Journal of hospital infection*.
429 2011;79(2):151-4.
- 430 25. Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, et al. A Multi-Center Prospective
431 Derivation and Validation of a Clinical Prediction Tool for Severe *Clostridium difficile* Infection. *PloS*
432 *one*. 2015;10(4):e0123405.
- 433 26. Rubin MS, Bodenstern LE, Kent KC. Severe *Clostridium difficile* colitis. *Diseases of the colon*
434 *and rectum*. 1995;38(4):350-4.
- 435 27. Valiquette L, Pépin J, Do XV, Nault V, Beaulieu AA, Bédard J, et al. Prediction of complicated
436 *Clostridium difficile* infection by pleural effusion and increased wall thickness on computed
437 tomography. *Clin Infect Dis*. 2009;49(4):554-60.
- 438 28. Velazquez-Gomez I, Rocha-Rodriguez R, Toro DH, Gutierrez-Nuñez JJ, Gonzalez G, Saavedra S.
439 A Severity Score Index for *Clostridium difficile* Infection. *Infectious Diseases in Clinical Practice*.
440 2008;16(6):376-8.
- 441 29. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as
442 predictors of mortality in *Clostridium difficile* infection and derivation of the ARC predictive score.
443 *The Journal of hospital infection*. 2011;79(4):359-63.

- 444 30. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated
445 disease and mortality among the elderly critically ill. *Critical care medicine*. 2009;37(9):2583-9.
- 446 31. Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical M, Infectious D. European
447 Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for
448 Clostridium difficile infection (CDI). *Clin Microbiol Infect*. 2009;15(12):1067-79.
- 449 32. J. van Prehn ER, E.H. Vogelzang, E. Bouza, A. Hristea, B. Guery, M. Krutova, T. Norén, F.
450 Allerberger, J. Coia, A. Goorhuis, T. M. van Rossen, R.E. Ooijselaar, K. Burns, B.R. Scharvik Olesen, S.
451 Tschudin-Sutter, M. H. Wilcox, M. Vehreschild, F. Fitzpatrick, E.J. Kuijper. European Society of Clinical
452 Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for
453 Clostridioides difficile infection in adults. submitted to the ESCMID for (public) approval. 2021.
- 454 33. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice
455 Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious
456 Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
457 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*.
458 2018;66(7):e1-e48.
- 459 34. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al.
460 Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *Am J*
461 *Gastroenterol*. 2013;108(4):478-98; quiz 99.
- 462 35. Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P, et
463 al. Emergence of Clostridium difficile-associated disease in North America and Europe. *Clin Microbiol*
464 *Infect*. 2006;12 Suppl 6:2-18.
- 465 36. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies
466 of prognostic factors. *Ann Intern Med*. 2013;158(4):280-6.
- 467 37. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the
468 quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst*
469 *Rev*. 2013;2:71.
- 470 38. Alicino C, Giacobbe DR, Durando P, Bellina D, AM DIB, Paganino C, et al. Increasing incidence
471 of Clostridium difficile infections: results from a 5-year retrospective study in a large teaching
472 hospital in the Italian region with the oldest population. *Epidemiology and infection*.
473 2016;144(12):2517-26.
- 474 39. Ananthakrishnan AN, Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane I, et al. Predictors
475 of severe outcomes associated with Clostridium difficile infection in patients with inflammatory
476 bowel disease. *Alimentary pharmacology & therapeutics*. 2012;35(7):789-95.
- 477 40. Andrews CN, Rouboud J, Kassen BO, Enns R. Clostridium difficile-associated diarrhea:
478 predictors of severity in patients presenting to the emergency department. *Canadian journal of*
479 *gastroenterology = Journal canadien de gastroenterologie*. 2003;17(6):369-73.
- 480 41. Archbald-Pannone LR, McMurry TL, Guerrant RL, Warren CA. Delirium and other clinical
481 factors with Clostridium difficile infection that predict mortality in hospitalized patients. *American*
482 *journal of infection control*. 2015;43(7):690-3.
- 483 42. Atamna A, Yahav D, Eliakim-Raz N, Goldberg E, Ben-Zvi H, Barsheshet A, et al. The effect of
484 statins on the outcome of Clostridium difficile infection in hospitalized patients. *European Journal of*
485 *Clinical Microbiology and Infectious Diseases*. 2016;35(5):779-84.
- 486 43. Barker AK, Van Galen A, Sethi AK, Shirley D, Safdar N. Tobacco use as a screener for
487 Clostridium difficile infection outcomes. *The Journal of hospital infection*. 2018;98(1):36-9.
- 488 44. Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, et al. Impact of the
489 NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium
490 difficile infection. *Anaerobe*. 2017;48:1-6.
- 491 45. Berry CE, Davies KA, Owens DW, Wilcox MH. Is there a relationship between the presence of
492 the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)?
493 *European journal of clinical microbiology & infectious diseases : official publication of the European*
494 *Society of Clinical Microbiology*. 2017;36(12):2405-15.

- 495 46. Boone JH, Archbald-Pannone LR, Wickham KN, Carman RJ, Guerrant RL, Franck CT, et al.
496 Ribotype 027 *Clostridium difficile* infections with measurable stool toxin have increased lactoferrin
497 and are associated with a higher mortality. *European journal of clinical microbiology & infectious*
498 *diseases : official publication of the European Society of Clinical Microbiology*. 2014;33(6):1045-51.
- 499 47. Caupenne A, Ingrand P, Ingrand I, Forestier E, Roubaud-Baudron C, Gavazzi G, et al. Acute
500 *Clostridioides difficile* Infection in Hospitalized Persons Aged 75 and Older: 30-Day Prognosis and Risk
501 Factors for Mortality. *Journal of the American Medical Directors Association*. 2019.
- 502 48. Charilaou P, Devani K, John F, Kanna S, Ahlawat S, Young M, et al. Acute kidney injury impact
503 on inpatient mortality in *Clostridium difficile* infection: A national propensity-matched study. *Journal*
504 *of gastroenterology and hepatology*. 2018;33(6):1227-33.
- 505 49. Chintanaboina J, Navabi S, Suchniak-Mussari K, Stern B, Bedi S, Lehman EB, et al. Predictors
506 of 30-Day Mortality in Hospitalized Patients with *Clostridium difficile* Infection. *SouthMedJ*.
507 2017;110(8):546-9.
- 508 50. Clohessy P, Merif J, Post JJ. Severity and frequency of community-onset *Clostridium difficile*
509 infection on an Australian tertiary referral hospital campus. *International Journal of Infectious*
510 *Diseases*. 2014;29:152-5.
- 511 51. Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, et al. *Clostridium difficile* fecal
512 toxin level is associated with disease severity and prognosis. *United European gastroenterology*
513 *journal*. 2018;6(5):773-80.
- 514 52. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-
515 term mortality in hospitalized patients with *clostridium difficile*-associated disease. *Am J*
516 *Gastroenterol*. 2010;105(9):2040-9.
- 517 53. De Francesco MA, Lorenzin G, Piccinelli G, Corbellini S, Bonfanti C, Caruso A. Correlation
518 between *tcdB* gene PCR cycle threshold and severe *Clostridium difficile* disease. *Anaerobe*.
519 2019;59:141-4.
- 520 54. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. *C. difficile* colitis--predictors of
521 fatal outcome. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the*
522 *Alimentary Tract*. 2010;14(2):315-22.
- 523 55. Figh ML, Zoog ESL, Moore RA, Dart BWt, Heath G, Butler RM, et al. External Validation of
524 Velazquez-Gomez Severity Score Index and ATLAS Scores and the Identification of Risk Factors
525 Associated with Mortality in *Clostridium difficile* Infections. *The American surgeon*.
526 2017;83(12):1347-51.
- 527 56. Fountain EM, Moses MC, Park LP, Woods CW, Arepally GM. Thrombocytopenia in
528 hospitalized patients with severe *clostridium difficile* infection. *Journal of thrombosis and*
529 *thrombolysis*. 2017;43(1):38-42.
- 530 57. Fujii L, Fasolino J, Crowell MD, Dibaise JK. Appendectomy and risk of *clostridium difficile*
531 recurrence. *Infectious Diseases in Clinical Practice*. 2013;21(1):28-32.
- 532 58. Hanania A, Jiang ZD, Smiley C, Lasco T, Garey KW, DuPont HL. Fecal calprotectin in the
533 diagnosis of *clostridium difficile* infection. *Infectious Diseases in Clinical Practice*. 2016;24(1):31-4.
- 534 59. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe *Clostridium*
535 *difficile*-associated disease. *Emerging infectious diseases*. 2009;15(3):415-22.
- 536 60. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, et al. A portrait of the
537 geographic dissemination of the *Clostridium difficile* North American pulsed-field type 1 strain and
538 the epidemiology of *C. difficile*-associated disease in Quebec. *Clin Infect Dis*. 2007;44(2):238-44.
- 539 61. Huttunen R, Vuento R, Syrjanen J, Tissari P, Aittoniemi J. Case fatality associated with a
540 hypervirulent strain in patients with culture-positive *Clostridium difficile* infection: a retrospective
541 population-based study. *International journal of infectious diseases : IJID : official publication of the*
542 *International Society for Infectious Diseases*. 2012;16(7):e532-5.
- 543 62. Kassam Z, Cribb Fabersunne C, Smith MB, Alm EJ, Kaplan GG, Nguyen GC, et al. *Clostridium*
544 *difficile* associated risk of death score (CARDS): a novel severity score to predict mortality among
545 hospitalised patients with *C. difficile* infection. *Alimentary pharmacology & therapeutics*.
546 2016;43(6):725-33.

- 547 63. Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, et al. Analysis of 30-
548 day mortality for clostridium difficile-associated disease in the ICU setting. *Chest*. 2007;132(2):418-
549 24.
- 550 64. Khanafer N, Barbut F, Eckert C, Perraud M, Demont C, Luxemburger C, et al. Factors
551 predictive of severe Clostridium difficile infection depend on the definition used. *Anaerobe*.
552 2016;37:43-8.
- 553 65. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The
554 epidemiology of community-acquired Clostridium difficile infection: a population-based study. *Am J*
555 *Gastroenterol*. 2012;107(1):89-95.
- 556 66. Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of
557 mortality in hospitalized adults with Clostridium difficile infection. *Internal and emergency medicine*.
558 2016;11(5):657-65.
- 559 67. Khanna S, Keddis MT, Noheria A, Baddour LM, Pardi DS. Acute kidney injury is an
560 independent marker of severity in Clostridium difficile infection: a nationwide survey. *Journal of*
561 *clinical gastroenterology*. 2013;47(6):481-4.
- 562 68. Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, et al. Fecal Calprotectin Level Reflects the
563 Severity of Clostridium difficile Infection. *Annals of laboratory medicine*. 2017;37(1):53-7.
- 564 69. Kim J, Kim Y, Pai H. Clinical Characteristics and Treatment Outcomes of Clostridium difficile
565 Infections by PCR Ribotype 017 and 018 Strains. *PloS one*. 2016;11(12):e0168849.
- 566 70. Kulaylat AS, Buonomo EL, Scully KW, Hollenbeak CS, Cook H, Petri WA, Jr., et al. Development
567 and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With
568 Peripheral Eosinopenia on Admission for Clostridium difficile Infection. *JAMA surgery*.
569 2018;153(12):1127-33.
- 570 71. Lee HC, Kim KO, Jeong YH, Lee SH, Jang BI, Kim TN. Clinical Outcomes in Hospitalized Patients
571 with Clostridium difficile Infection by Age Group. *The Korean journal of gastroenterology = Taehan*
572 *Sohwagi Hakhoe chi*. 2016;67(2):81-6.
- 573 72. Leibovici-Weissman Y, Atamna A, Schlesinger A, Eliakim-Raz N, Bishara J, Yahav D. Risk factors
574 for short- and long-term mortality in very old patients with Clostridium difficile infection: A
575 retrospective study. *Geriatrics & gerontology international*. 2017;17(10):1378-83.
- 576 73. Mascart G, Delmee M, Van Broeck J, Cytryn E, Karmali R, Cherifi S. Impact of ribotype 027 on
577 Clostridium difficile infection in a geriatric department. *European journal of clinical microbiology &*
578 *infectious diseases : official publication of the European Society of Clinical Microbiology*.
579 2013;32(9):1177-82.
- 580 74. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-associated
581 Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of
582 severe outcome and mortality. *Clin Infect Dis*. 2010;50(2):194-201.
- 583 75. Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with
584 complications and mortality in patients with Clostridium difficile infection. *Clin Infect Dis*.
585 2011;53(12):1173-8.
- 586 76. Ogielska M, Lanotte P, Le Brun C, Valentin AS, Garot D, Tellier AC, et al. Emergence of
587 community-acquired Clostridium difficile infection: the experience of a French hospital and review of
588 the literature. *International journal of infectious diseases : IJID : official publication of the*
589 *International Society for Infectious Diseases*. 2015;37:36-41.
- 590 77. Patel UC, Wieczorkiewicz JT, Tuazon J. Evaluation of advanced age as a risk factor for severe
591 Clostridium difficile infection. *Journal of Clinical Gerontology and Geriatrics*. 2016;7(1):12-6.
- 592 78. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-
593 associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
594 *Cmaj*. 2004;171(5):466-72.
- 595 79. Polivkova S, Krutova M, Petrlova K, Benes J, Nyc O. Clostridium difficile ribotype 176 - A
596 predictor for high mortality and risk of nosocomial spread? *Anaerobe*. 2016;40:35-40.

- 597 80. Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C, et al. Poor functional status as a risk
598 factor for severe *Clostridium difficile* infection in hospitalized older adults. *Journal of the American*
599 *Geriatrics Society*. 2013;61(10):1738-42.
- 600 81. Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, et al. *Clostridium difficile* ribotype
601 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and
602 mortality. *Clin Infect Dis*. 2015;61(2):233-41.
- 603 82. Reigadas E, Alcalá L, Marin M, Martín A, Iglesias C, Bouza E. Role of binary toxin in the
604 outcome of *Clostridium difficile* infection in a non-027 ribotype setting. *Epidemiology and Infection*.
605 2016;144(2):268-73.
- 606 83. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant
607 *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Arch Surg*. 2009;144(5):433-
608 9; discussion 9-40.
- 609 84. Scardina T, Labuszewski L, Pacheco SM, Adams W, Schreckenberger P, Johnson S. *Clostridium*
610 *difficile* infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in
611 a non-epidemic setting. *Infect Control Hosp Epidemiol*. 2015;36(3):280-6.
- 612 85. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, et al. NAP1 strain type predicts
613 outcomes from *Clostridium difficile* infection. *Clin Infect Dis*. 2014;58(10):1394-400.
- 614 86. Serafino S, Consonni D, Migone De Amicis M, Sisto F, Domeniconi G, Formica S, et al. Clinical
615 outcomes of *Clostridium difficile* infection according to strain type. A prospective study in medical
616 wards. *European journal of internal medicine*. 2018;54:21-6.
- 617 87. Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, et al.
618 Clinical factors associated with development of severe-complicated *Clostridium difficile* infection.
619 *Clinical gastroenterology and hepatology : the official clinical practice journal of the American*
620 *Gastroenterological Association*. 2013;11(11):1466-71.
- 621 88. Starzengruber P, Segagni Lusignani L, Wrba T, Mitteregger D, Indra A, Graninger W, et al.
622 Severe *Clostridium difficile* infection: incidence and risk factors at a tertiary care university hospital in
623 Vienna, Austria. *Wiener klinische Wochenschrift*. 2014;126(13-14):427-30.
- 624 89. Tamez-Torres KM, Torres-Gonzalez P, Leal-Vega F, Garcia-Alderete A, Lopez Garcia NI,
625 Mendoza-Aguilar R, et al. Impact of *Clostridium difficile* infection caused by the NAP1/RT027 strain
626 on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care
627 center. *International journal of infectious diseases : IJID : official publication of the International*
628 *Society for Infectious Diseases*. 2017;65:44-9.
- 629 90. Taori SK, Wroe A, Hardie A, Gibb AP, Poxton IR. A prospective study of community-associated
630 *Clostridium difficile* infections: the role of antibiotics and co-infections. *The Journal of Infection*.
631 2014;69(2):134-44.
- 632 91. Tschudin-Sutter S, Braissant O, Erb S, Strandén A, Bonkat G, Frei R, et al. Growth Patterns of
633 *Clostridium difficile* - Correlations with Strains, Binary Toxin and Disease Severity: A Prospective
634 Cohort Study. *PloS one*. 2016;11(9):e0161711.
- 635 92. van der Wilden GM, Chang Y, Cropano C, Subramanian M, Schipper IB, Yeh DD, et al.
636 Fulminant *Clostridium difficile* colitis: prospective development of a risk scoring system. *The journal*
637 *of trauma and acute care surgery*. 2014;76(2):424-30.
- 638 93. Vojtilova L, Freibergova M, Jurankova J, Bortlicek Z, Husa P. Epidemiological factors
639 influencing the development of relapsing and severe *Clostridium difficile* infection. *Epidemiologie,*
640 *mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske*
641 *spolecnosti JE Purkyne*. 2014;63(1):27-35.
- 642 94. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, et al. *Clostridium difficile* Ribotype Does Not
643 Predict Severe Infection. *Clin Infect Dis*. 2012;55(12):1661-8.
- 644 95. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, et al. Relationship between
645 bacterial strain type, host biomarkers, and mortality in *Clostridium difficile* infection. *Clin Infect Dis*.
646 2013;56(11):1589-600.

- 647 96. Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M, Citron D, et al. Predictors of death
648 after *Clostridium difficile* infection: a report on 128 strain-typed cases from a teaching hospital in the
649 United Kingdom. *Clin Infect Dis*. 2010;50(12):e77-81.
- 650 97. Xu Q, Chen Y, Gu S, Lv T, Zheng B, Shen P, et al. Hospital-acquired *Clostridium difficile*
651 infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university
652 hospital. *Scientific reports*. 2017;7(1):9645.
- 653 98. Yong FA, Alvarado AM, Wang H, Tsai J, Estes NC. Appendectomy: a risk factor for colectomy
654 in patients with *Clostridium difficile*. *American journal of surgery*. 2015;209(3):532-5.
- 655 99. Miller R, Morillas JA, Brizendine KD, Fraser TG. Predictors of *Clostridioides difficile* Infection-
656 Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin
657 Enzyme Immunoassay-Negative Patients. *J Clin Microbiol*. 2020;58(3).
- 658 100. Menon A, Perry DA, Motyka J, Weiner S, Standke A, Penkevich A, et al. Changes in the
659 Association between Diagnostic Testing Method, PCR Ribotype, and Clinical Outcomes from
660 *Clostridioides difficile* Infection: One Institution's Experience. *Clin Infect Dis*. 2020.
- 661 101. Korac M, Rupnik M, Nikolic N, Jovanovic M, Tosic T, Malinic J, et al. *Clostridioides difficile*
662 ribotype distribution in a large teaching hospital in Serbia. *Gut Pathog*. 2020;12:26.
- 663 102. Essrani R, Saturno D, Mehershahi S, Essrani RK, Hossain MR, Ravi SJK, et al. The Impact of
664 Appendectomy in *Clostridium difficile* Infection and Length of Hospital Stay. *Cureus*.
665 2020;12(9):e10342.
- 666 103. Choi B, Wong KK, Dunn AN, Butler R, Fraser TG, Procop GW, et al. Real-time polymerase
667 chain reaction (PCR) cycle threshold and *Clostridioides difficile* infection outcomes. *Infect Control*
668 *Hosp Epidemiol*. 2021:1-7.
- 669 104. Avni T, Hammud H, Itzhaki O, Gafter-Gvili A, Rozen-Zvi B, Ben-Zvi H, et al. The significance of
670 acute kidney injury in *Clostridioides difficile* infection. *Int J Clin Pract*. 2021;75(3).
- 671 105. Mendez-Bailon M, Jimenez-Garcia R, Hernandez-Barrera V, Miguel-Diez J, Miguel-Yanes JM,
672 Munoz-Rivas N, et al. Heart Failure Is a Risk Factor for Suffering and Dying of *Clostridium difficile*
673 Infection. Results of a 15-Year Nationwide Study in Spain. *J Clin Med*. 2020;9(3).
- 674 106. Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, et al. Risk prediction for 30-day
675 mortality among patients with *Clostridium difficile* infections: a retrospective cohort study.
676 *Antimicrob Resist Infect Control*. 2019;8:175.
- 677 107. Vata A, Miftode IL, Dorneanu OS, Vata LG, Miftode D, Trifan A, et al. CLOSTRIDIUM DIFFICILE
678 INFECTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. THE EXPERIENCE OF AN INFECTIOUS
679 DISEASES HOSPITAL FROM NORTH-EASTERN ROMANIA. *Med-Surg J*. 2019;123(3):506-12.
- 680 108. Mani NS, Lynch JB, Fang FC, Chan JD. Risk Factors for BI/NAP1/027 *Clostridioides difficile*
681 Infections and Clinical Outcomes Compared With Non-NAP1 Strains. *Open Forum Infect Dis*.
682 2019;6(12):4.
- 683 109. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and
684 outcomes in *Clostridium difficile* infection: a population-based study. *Mayo Clinic proceedings*.
685 2012;87(7):636-42.
- 686 110. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in
687 outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic
688 validation study of *C difficile* infection. *The Lancet Infectious diseases*. 2013;13(11):936-45.
- 689 111. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al.
690 *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet*. 2011;377(9759):63-73.
- 691 112. Argamany JR, Lee GC, Duhon BD, Zeidan AR, Young EH, Reveles KR. A possible association
692 between statin use and improved *Clostridioides difficile* infection mortality in veterans. *PloS one*.
693 2019;14(5):e0217423.
- 694 113. Leal J, Ronksley P, Henderson EA, Conly J, Manns B. Predictors of mortality and length of stay
695 in patients with hospital-acquired *Clostridioides difficile* infection: a population-based study in
696 Alberta, Canada. *The Journal of hospital infection*. 2019;103(1):85-91.

- 697 114. Nagayoshi Y, Yamamoto K, Sato S, Suyama N, Izumikawa T, Izumikawa K, et al. Clinical
698 significance of a positive *Clostridioides difficile* glutamate dehydrogenase test on the outcomes of
699 hospitalized older patients. *Geriatrics & gerontology international*. 2020;20(12):1138-44.
- 700 115. Patel H, Makker J, Vakde T, Shaikh D, Badipatla K, Dunne J, et al. Nonsteroidal Anti-
701 Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with *Clostridium difficile*
702 Infection. *Clinical and experimental gastroenterology*. 2019;12:449-56.
- 703 116. Tay HL, Chow A, Ng TM, Lye DC. Risk factors and treatment outcomes of severe *Clostridioides*
704 *difficile* infection in Singapore. *Scientific reports*. 2019;9(1):13440.
- 705 117. Origuen J, Orellana MA, Fernandez-Ruiz M, Corbella L, San Juan R, Ruiz-Ruigomez M, et al.
706 Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in
707 *Clostridium difficile* Infection: a Retrospective Cohort Study. *J Clin Microbiol*. 2019;57(2).
- 708 118. Milenkovic B, Suljagic V, Peric A, Dragojevic-Simic V, Tarabar O, Milanovic M, et al. Outcomes
709 of *Clostridioides difficile* infection in adult cancer and non-cancer patients hospitalised in a tertiary
710 hospital: a prospective cohort study. *Eur J Hosp Pharm*. 2021.
- 711 119. Lopez-Cardenas S, Torres-Martos E, Mora-Delgado J, Sanchez-Calvo JM, Santos-Pena M,
712 Zapata Lopez A, et al. The prognostic value of toxin B and binary toxin in *Clostridioides difficile*
713 infection. *Gut Microbes*. 2021:1-8.
- 714 120. Enoch DA, Murray-Thomas T, Adomakoh N, Dedman D, Georgopali A, Francis NA, et al. Risk
715 of complications and mortality following recurrent and non-recurrent *Clostridioides difficile* infection:
716 a retrospective observational database study in England. *The Journal of hospital infection*.
717 2020;106(4):793-803.
- 718 121. Carlson TJ, Endres BT, Le Pham J, Gonzales-Luna AJ, Alnezary FS, Nebo K, et al. Eosinopenia
719 and Binary Toxin Increase Mortality in Hospitalized Patients With *Clostridioides difficile* Infection.
720 *Open Forum Infect Dis*. 2020;7(1):ofz552.
- 721 122. Abdelfatah M, Nayfe R, Nijim A, Enriquez K, Ali E, Watkins RR, et al. Factors Predicting
722 Recurrence of *Clostridium difficile* Infection (CDI) in Hospitalized Patients: Retrospective Study of
723 More Than 2000 Patients. *J Investig Med*. 2015;63(5):747-51.
- 724 123. Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of *Clostridioides*
725 *difficile* recurrence across a national cohort of veterans in outpatient, acute, and long-term care
726 settings. *Am J Health Syst Pharm*. 2019;76(9):581-90.
- 727 124. Avni T, Babitch T, Ben-Zvi H, Hijazi R, Ayada G, Atamna A, et al. *Clostridioides difficile*
728 infection in immunocompromised hospitalized patients is associated with a high recurrence rate. *Int J*
729 *Infect Dis*. 2020;90:237-42.
- 730 125. Carpenter BP, Hennessey EK, Bryant AM, Khoury JA, Crannage AJ. Identification of Factors
731 Impacting Recurrent *Clostridium difficile* Infection and Development of a Risk Evaluation Tool. *J*
732 *Pharm Pharm Sci*. 2016;19(3):349-56.
- 733 126. Dharbhamulla N, Abdelhady A, Domadia M, Patel S, Gaughan J, Roy S. Risk Factors Associated
734 With Recurrent *Clostridium difficile* Infection. *J Clin Med Res*. 2019;11(1):1-6.
- 735 127. Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR.
736 Antimicrobial use and risk for recurrent *Clostridium difficile* infection. *Am J Med*. 2011;124(11):1081
737 e1-7.
- 738 128. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of first
739 recurrence of *Clostridium difficile* infection: implications for initial management. *Clin Infect Dis*.
740 2012;55 Suppl 2:S77-87.
- 741 129. Falcone M, Tiseo G, Iraci F, Raponi G, Goldoni P, Delle Rose D, et al. Risk factors for
742 recurrence in patients with *Clostridium difficile* infection due to 027 and non-027 ribotypes. *Clin*
743 *Microbiol Infect*. 2019;25(4):474-80.
- 744 130. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for
745 recurrent *Clostridium difficile* infection among inpatients. *Am J Gastroenterol*. 2013;108(11):1794-
746 801.
- 747 131. Fujii LF, J. Crowell, M. DiBaise, K. Appendectomy and Risk of *Clostridium difficile* Recurrence.
748 *Infectious Diseases in Clinical Practice*. 2013;21(1):28-32.

- 749 132. Im GY, Modayil RJ, Lin CT, Geier SJ, Katz DS, Feuerman M, et al. The appendix may protect
750 against *Clostridium difficile* recurrence. *Clinical gastroenterology and hepatology : the official clinical*
751 *practice journal of the American Gastroenterological Association*. 2011;9(12):1072-7.
- 752 133. Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of
753 *Clostridioides (Clostridium) difficile* infection in Japan: A nationwide real-world analysis using a large
754 hospital-based administrative dataset. *J Infect Chemother*. 2019;25(8):615-20.
- 755 134. Lavergne V, Beausejour Y, Pichette G, Ghannoum M, Su SH. Lymphopenia as a novel marker
756 of *Clostridium difficile* infection recurrence. *The Journal of infection*. 2013;66(2):129-35.
- 757 135. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for
758 recurrent *Clostridium difficile* infection. *Arch Intern Med*. 2010;170(9):772-8.
- 759 136. Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, et al. Effect of age on
760 treatment outcomes in *Clostridium difficile* infection. *Journal of the American Geriatrics Society*.
761 2013;61(2):222-30.
- 762 137. Lupse M, Flonta M, Cioara A, Filipescu I, Todor N. Predictors of first recurrence in *Clostridium*
763 *difficile*-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral
764 center. *J Gastrointestin Liver Dis*. 2013;22(4):397-403.
- 765 138. Marincu I, Bratosin F, Vidican I, Cerbu B, Turaiche M, Tirnea L, et al. Predictive Factors for the
766 First Recurrence of *Clostridioides difficile* Infection in the Elderly from Western Romania. *Medicina*
767 (Kaunas). 2020;56(9).
- 768 139. McDonald EG, Milligan J, Frenette C, Lee TC. Continuous Proton Pump Inhibitor Therapy and
769 the Associated Risk of Recurrent *Clostridium difficile* Infection. *JAMA Intern Med*. 2015;175(5):784-
770 91.
- 771 140. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent
772 *Clostridium difficile* disease: epidemiology and clinical characteristics. *Infect Control Hosp Epidemiol*.
773 1999;20(1):43-50.
- 774 141. Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y. Risk factors for recurrent *Clostridium*
775 *difficile* infection in a tertiary hospital in Israel. *European journal of clinical microbiology & infectious*
776 *diseases : official publication of the European Society of Clinical Microbiology*. 2018;37(7):1281-8.
- 777 142. Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, et al. Risk Factors Associated with
778 Recurrent *Clostridioides difficile* Infection. *Healthcare*. 2020;8(3):12.
- 779 143. Origüen J, Orellana M, Fernández-Ruiz M, Corbella L, San Juan R, Ruiz-Ruigómez M, et al.
780 Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in
781 *Clostridium difficile* Infection: a Retrospective Cohort Study. *J Clin Microbiol*. 2019;57(2).
- 782 144. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after
783 treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clin Infect Dis*. 2005;40(11):1591-7.
- 784 145. Rao K, Higgins PDR, Young VB. An Observational Cohort Study of *Clostridium difficile* Ribotype
785 027 and Recurrent Infection. *mSphere*. 2018;3(3).
- 786 146. Rodriguez-Pardo D, Almirante B, Bartolome RM, Pomar V, Mirelis B, Navarro F, et al.
787 Epidemiology of *Clostridium difficile* infection and risk factors for unfavorable clinical outcomes:
788 results of a hospital-based study in Barcelona, Spain. *J Clin Microbiol*. 2013;51(5):1465-73.
- 789 147. Rotramel A, Poritz LS, Messaris E, Berg A, Stewart DB. PPI therapy and albumin are better
790 predictors of recurrent *Clostridium difficile* colitis than choice of antibiotics. *Journal of*
791 *gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract*.
792 2012;16(12):2267-73.
- 793 148. van Beurden YH, Nezami S, Mulder CJJ, Vandenbroucke-Grauls C. Host factors are more
794 important in predicting recurrent *Clostridium difficile* infection than ribotype and use of antibiotics.
795 *Clin Microbiol Infect*. 2018;24(1):85 e1- e4.
- 796 149. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Risk factors for recurrent *Clostridium*
797 *difficile* infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a
798 retrospective cohort study. *BMC Infect Dis*. 2014;14:306.

- 799 150. Cadena J, Thompson GR, 3rd, Patterson JE, Nakashima B, Owens A, Echevarria K, et al. Clinical
800 predictors and risk factors for relapsing *Clostridium difficile* infection. *Am J Med Sci*. 2010;339(4):350-
801 5.
- 802 151. Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor
803 for recurrence of *Clostridium difficile* infection in the acute care hospital setting. *American journal of*
804 *infection control*. 2011;39(3):194-8.
- 805 152. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent
806 *Clostridium difficile* diarrhea: characteristics of and risk factors for patients enrolled in a prospective,
807 randomized, double-blinded trial. *Clin Infect Dis*. 1997;24(3):324-33.
- 808 153. Ryu HS, Kim YS, Seo GS, Lee YM, Choi SC. Risk Factors for Recurrent *Clostridium difficile*
809 Infection. *Intest Res*. 2012;10(2):176-82.
- 810 154. Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB. Renal Impairment, *C.*
811 *difficile* Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data
812 From 2 Randomized Clinical Trials. *Open Forum Infect Dis*. 2020;7(7):ofaa248.
- 813 155. Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump
814 inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients
815 with *Clostridium difficile*-associated diarrhoea. *BMJ Open Gastroenterol*. 2015;2(1):e000028.
- 816 156. Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, et al. Bezlotoxumab for
817 Prevention of Recurrent *Clostridium difficile* Infection in Patients at Increased Risk for Recurrence.
818 *Clin Infect Dis*. 2018;67(5):649-56.
- 819 157. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, et al. Fidaxomicin versus
820 vancomycin for *Clostridium difficile* infection: meta-analysis of pivotal randomized controlled trials.
821 *Clin Infect Dis*. 2012;55 Suppl 2:S93-103.
- 822 158. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for
823 Prevention of Recurrent *Clostridium difficile* Infection. *N Engl J Med*. 2017;376(4):305-17.
- 824 159. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus
825 vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011;364(5):422-31.
- 826 160. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus
827 vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind,
828 non-inferiority, randomised controlled trial. *The Lancet Infectious diseases*. 2012;12(4):281-9.
- 829 161. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
830 comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases*.
831 1987;40(5):373-83.
- 832 162. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and
833 mortality in *Clostridium difficile* infection: a systematic review. *PLoS one*. 2014;9(6):e98400.
- 834 163. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk factors for
835 recurrent *Clostridium difficile* infection: a systematic review and meta-analysis. *Infect Control Hosp*
836 *Epidemiol*. 2015;36(4):452-60.
- 837 164. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent
838 *Clostridium difficile* infection. *The Journal of hospital infection*. 2008;70(4):298-304.
- 839 165. Zhang VRY, Woo ASJ, Scaduto C, Cruz MTK, Tan YY, Du H, et al. Systematic review on the
840 definition and predictors of severe *Clostridioides difficile* infection. *Journal of gastroenterology and*
841 *hepatology*. 2021;36(1):89-104.
- 842 166. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence
843 risk research. *Jama*. 2011;305(8):822-3.
- 844 167. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P,
845 Bruminhent J. The Risks of Incident and Recurrent *Clostridium difficile*-Associated Diarrhea in Chronic
846 Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis.
847 *Digestive diseases and sciences*. 2015;60(10):2913-22.
- 848 168. Dalal RS, Allegretti JR. Diagnosis and management of *Clostridioides difficile* infection in
849 patients with inflammatory bowel disease. *Current opinion in gastroenterology*. 2021;37(4):336-43.

850 169. Beaugard-Paultre C, Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, et al.
851 External validation of clinical prediction rules for complications and mortality following Clostridioides
852 difficile infection. PloS one. 2019;14(12):e0226672.
853 170. van Beurden YH, Hensgens MPM, Dekkers OM, Le Cessie S, Mulder CJJ, Vandenbroucke-
854 Grauls C. External Validation of Three Prediction Tools for Patients at Risk of a Complicated Course of
855 Clostridium difficile Infection: Disappointing in an Outbreak Setting. Infect Control Hosp Epidemiol.
856 2017;38(8):897-905.
857 171. van Rossen TM, van Dijk LJ, Heymans MW, Dekkers OM, Vandenbroucke-Grauls C, van
858 Beurden YH. External validation of two prediction tools for patients at risk for recurrent Clostridioides
859 difficile infection. Therapeutic advances in gastroenterology. 2021;14:1756284820977385.

860

861 **Supplementary data**

862 **PICO's**

863 Two PICO's were formulated:

864 Prognosis severe CDI:

865 P: patients with CDI
866 I: presence of clinical and laboratory parameters
867 C: absence of clinical and laboratory parameters
868 O: severe CDI

869 Prognosis recurrent CDI:

870 P: patients with CDI
871 I: presence of clinical and laboratory parameters
872 C: absence of clinical and laboratory parameters
873 O: recurrent CDI

874 **Literature search prognosis severe CDI - Pubmed**

875 (("Clostridium difficile Infection"[tw] OR "Clostridium difficile Infections"[tw] OR "C difficile
876 Infection"[tw] OR "C difficile Infections"[tw] OR "clostridioides difficile infection"[tw] OR
877 ("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C difficile"[ti] OR "c diff"[ti] OR
878 "clostridioides difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
879 "Clostridium Infection"[ti])) OR ("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C
880 difficile"[ti] OR "difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
881 "Clostridium Infection"[ti] OR "Infection"[majr] OR "infection"[ti] OR "infections"[ti] OR infect*[ti] OR
882 "inflammation"[ti] OR inflammat*[ti] OR "Enterocolitis"[majr] OR "Enterocolitis"[ti] OR "colitis"[ti] OR
883 "Digestive System Diseases"[majr]))))

884 **AND**

885 ("Prognosis"[Mesh] OR prognos*[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR
886 "clinical parameter"[tw] OR "clinical parameters"[tw] OR "laboratory parameter"[tw] OR "laboratory
887 parameters"[tw] OR "Age Factors"[mesh] OR "Age Factor"[tw] OR "Age Factors"[tw] OR "Age"[tiab]
888 OR "Age Reporting"[tw] OR "Leukocytosis"[Mesh] OR "Leukocytosis"[tw] OR "Pleocytosis"[tw] OR
889 "leucocytosis"[tw] OR "Leukemoid Reaction"[tw] OR "Lymphocytosis"[tw] OR (decreas*[tw] AND
890 ("Serum Albumin"[mesh] OR "blood albumin"[tw] OR "serum albumin"[tw])) OR (("rise"[tw] OR

891 "rising"[tw] OR rise*[tw] OR increas*[tw]) AND ("serum creatinine"[tw] OR
892 "Creatinine/blood"[mesh]) OR "severe underlying disease"[tw] OR "severe underlying diseases"[tw]
893 OR "severe underlying illness"[tw] OR "severe underlying illnesses"[tw] OR "severe underlying
894 condition"[tw] OR "severe underlying conditions"[tw] OR "Immunologic Deficiency
895 Syndromes"[Mesh] OR "Immunologic Deficiency"[tw] OR "Immune Deficiency"[tw] OR
896 "immunodeficiency"[tw] OR "Immunologic Deficiencies"[tw] OR "Immune Deficiencies"[tw] OR
897 "immunodeficiencies"[tw] OR "Immunocompromised Host"[Mesh] OR "Immunocompromised"[tw]
898 OR (strain*[tw] AND ribotype*[tw]))

899 **AND**

900 ("severe clostridium difficile"[tw] OR "severe cdi"[tw] OR "severe cd"[tw] OR "disease severity"[tw]
901 OR "illness severity"[tw] OR "severity of disease"[tw] OR "severity of illness"[tw] OR "severe"[tw] OR
902 "severity"[tw] OR sever*[tw])

903 **NOT**

904 (("Case Reports"[ptyp] OR "case report"[ti]) NOT ("Review"[ptyp] OR "review"[ti] OR "Clinical
905 Study"[ptyp] OR "trial"[ti] OR "RCT"[ti])) NOT ("Animals"[mesh] NOT "Humans"[mesh])

906 **AND**

907 english[la])

908 **Literature search prognosis recurrent CDI - Pubmed:**

909 (("Clostridium difficile Infection"[tw] OR "Clostridium difficile Infections"[tw] OR "C difficile
910 Infection"[tw] OR "C difficile Infections"[tw] OR "clostridioides difficile infection"[tw] OR
911 ("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C difficile"[ti] OR "c diff"[ti] OR
912 "clostridioides difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
913 "Clostridium Infection"[ti])) OR (("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C
914 difficile"[ti] OR "difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
915 "Clostridium Infection"[ti] OR "Infection"[majr] OR "infection"[ti] OR "infections"[ti] OR infect*[ti] OR
916 "inflammation"[ti] OR inflammat*[ti] OR "Enterocolitis"[majr] OR "Enterocolitis"[ti] OR "colitis"[ti] OR
917 "Digestive System Diseases"[majr]))

918 **AND**

919 ("Prognosis"[Mesh] OR prognos*[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR
920 "clinical parameter"[tw] OR "clinical parameters"[tw] OR "laboratory parameter"[tw] OR "laboratory
921 parameters"[tw] OR "Age Factors"[mesh] OR "Age Factor"[tw] OR "Age Factors"[tw] OR "Age"[tiab]
922 OR "Age Reporting"[tw] OR "severe underlying disease"[tw] OR "severe underlying diseases"[tw] OR
923 "severe underlying illness"[tw] OR "severe underlying illnesses"[tw] OR "severe underlying
924 condition"[tw] OR "severe underlying conditions"[tw] OR "Immunologic Deficiency
925 Syndromes"[Mesh] OR "Immunologic Deficiency"[tw] OR "Immune Deficiency"[tw] OR
926 "immunodeficiency"[tw] OR "Immunologic Deficiencies"[tw] OR "Immune Deficiencies"[tw] OR
927 "immunodeficiencies"[tw] OR "Immunocompromised Host"[Mesh] OR "Immunocompromised"[tw]
928 OR (strain*[tw] AND ribotype*[tw]) OR ((continued use*[tw] OR continuing use*[tw] OR prolonged
929 use*[tw]) AND (antibiotic*[tw] OR antibacterial*[tw] OR anti-biotic*[tw] OR anti-bacterial*[tw])) OR

930 "renal failure"[tw] OR "kidney failure"[tw] OR "Renal Insufficiency"[Mesh] OR "Renal
931 Insufficiency"[tw] OR "Kidney Insufficiency"[tw] OR "kidney injury"[tw] OR "renal injury"[tw] OR
932 previous infection*[tw] OR "Proton Pump Inhibitors"[Mesh] OR "Proton Pump
933 Inhibitors"[Pharmacological Action] OR "Proton Pump Inhibitors"[tw] OR "Proton Pump
934 Inhibitor"[tw] OR "initial severity"[tw] OR "initial disease severity"[tw] OR "initial illness severity"[tw]
935 OR (strain*[tw] AND ribotype*[tw]))

936 **AND**

937 ("recurrent clostridium difficile"[tw] OR "recurrent cdi"[tw] OR "recurrent cd"[tw] OR
938 "Recurrence"[Mesh] OR recurr*[tw])

939 **NOT**

940 (("Case Reports"[ptyp] OR "case report"[ti]) NOT ("Review"[ptyp] OR "review"[ti] OR "Clinical
941 Study"[ptyp] OR "trial"[ti] OR "RCT"[ti])) NOT ("Animals"[mesh] NOT "Humans"[mesh])

942 **AND**

943 english[la])